

For Immediate Release  
17th November 2020

**Introducing Dr Vida a Pocket PCtR analysis system for RAPID covid-19 testing which requires no RNA extraction step.**

Lisbon, Portugal - STAB VIDA Ltd an innovative nucleic analysis technology and service company today announced the introduction of their new unique and patented Dr. Vida Pocket PCtR device for rapid covid-19 detection which is CE-IVD certified and now available.

The product, which is pocket sized, takes samples from nasopharyngeal swabs and performs direct genetic analysis with results generated on the connected mobile device (iOS or Android) within 52 minutes.

The system demonstrates improved sensitivity and specificity in rapid covid-19 testing compared to antigen based rapid testing systems.

Dr Orfeu Flores, CEO of STAB VIDA Ltd, explains that they saw a need for rapid testing at an early stage of the pandemic and realised that a rapid method based on nucleic acid detection would be beneficial as it provided direct detection of the virus in de-centralised settings where required, such as patients in ambulance who will require emergency surgery or community health care workers having the opportunity to quickly test their patients during home visits.

Dra Sandra Rebelo, Clinical pathology Service of Hospital São João, Porto, Portugal stated that “Dr. Vida Pocket PCtR product for isothermal amplification of the RNA is an easy to handle mini device, a very promising innovation. We used it for Covid-19, with full digital operation. We are very happy with the comparative trial”.

Patricia Silva, Certified Nurse, Lisbon, Portugal stated that “In the midst of a pandemic in which prevention and speed of action are the keys, I think the Dr. Vida Pocket PCtR is an innovative and very useful method, as it reduces the waiting time for the result during home testing, which enables us to screen and isolate infected people more quickly, minimizing the spread of the virus”.



**About STAB VIDA Ltd**

*Based in Caparica close to Lisbon on the technology park, STAB VIDA was founded in 2001 to provide DNA analysis services for life science researchers in Portugal, expanding into other European countries in 2010. From 2017 the company started their own technology development, the first product being a benchtop rapid nucleic acid and antigen test system for Borrelia detection.*

<https://www.doctorvida.com/>